A genetic association study of the mu opioid receptor and severe opioid dependence.
paper
Cited
Public
Unavailable
- Authors
- Crowley, James J; Oslin, David W; Patkar, Ashwin A; Gottheil, Edward; DeMaria, Peter A; O'Brien, Charles P; Berrettini, Wade H; Grice, Dorothy E
- Year
- 2003
- Journal
- Psychiatric genetics
- PMID
- 12960749
- DOI
- 10.1097/00041444-200309000-00006
OBJECTIVES: Twin, family and adoption studies have suggested that vulnerability to opioid dependence may be a partially inherited trait (Cadoret et al., 1986; Merikangas et al., 1998; Tsuang et al., 1998, 2001). Studies using animal models also support a role for genetic factors in opioid dependence, and point to a locus of major effect on mouse chromosome 10 (Berrettini et al., 1994; Alexander et al., 1996), which harbors the mu opioid receptor gene (Mor1) (Kozak et al., 1994). The gene encoding the human mu opioid receptor (OPRM1) is thus an obvious candidate gene for contributing to opioid dependence. A recent report (Hoehe et al., 2000) found a significant association between a specific combination of OPRM1 single nucleotide polymorphisms (SNPs) and substance dependence. METHODS: In the current study, we genotyped 213 subjects with severe opioid dependence (89 African-Americans, 124 European-Americans) and 196 carefully screened "supercontrol" subjects (96 African-Americans, 100 European-Americans) at five SNPs residing in the OPRM1 gene. The polymorphisms include three in the promoter region (T-1793A, -1699T insertion and A-1320G) and two in exon 1 (C+17T [Ala6Val] and A+118G [Asp40Asn]). RESULTS: Statistical analysis of the allele frequency differences between opioid-dependent and control subjects for each of the polymorphisms studied yielded P values in the range of 0.444-1.000. Haplotype analysis failed to identify any specific combination of SNPs associated with the phenotype. CONCLUSIONS: Despite reasonable statistical power we found no evidence of association between the five mu opioid receptor polymorphisms studied and severe opioid dependence in our sample. There were, however, significant allele frequency differences between African-Americans and European-Americans for all five polymorphisms, irrespective of drug-dependent status. Linkage disequilibrium analysis of the African-American genotypes indicated linkage disequilibrium (P<0.0001) across the five-polymorphism, 1911 base pair region. In addition, only four haplotypes of these five polymorphisms are predicted to exist in African-Americans.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Genomic factors associated with substance use disorder relapse: A critical review. | Al-Marzooqi N et al. | β | 2024 | β |
| OPRM1 Gene Polymorphism in Women with Alcohol Use Disorder. | BoroΕ A et al. | β | 2024 | β |
| Allele frequency and genotype distribution of the opioid receptor ΞΌ-1 (OPRM1) A118G polymorphism in the Western Saudi population. | Bagher AM et al. | β | 2023 | β |
| Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis. | Blum K et al. | β | 2023 | β |
| Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor Β΅1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms? | GondrΓ©-Lewis MC et al. | β | 2022 | β |
| A systems omics-based approach to decode substance use disorders and neuroadaptations. | Veerappa A et al. | β | 2021 | β |
| Differential behavioral functioning in the offspring of rats with high vs. low self-administration of the opioid agonist remifentanil. | Rezvani AH et al. | β | 2021 | β |
| Genetic susceptibility of opioid receptor genes polymorphism to drug addiction: A candidate-gene association study. | Al-Eitan LN et al. | β | 2021 | β |
| Genetic Vulnerability to Opioid Addiction. | Reed B et al. | β | 2021 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. | Abijo T et al. | β | 2020 | β |
| Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism. | Cornett EM et al. | β | 2020 | β |
| The Streetlight Effect: Reappraising the Study of Addiction in Light of the Findings of Genome-wide Association Studies. | Hall FS et al. | β | 2020 | β |
| A review of opioid addiction genetics. | Crist RC et al. | β | 2019 | β |
| Increased risk of intracranial hemorrhage in preterm infants with OPRM1 gene A118G polymorphism. | Cheng XR et al. | β | 2019 | β |
| <i>OPRM1</i> A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches. | Taqi MM et al. | β | 2019 | β |
| Labour analgesia; Molecular pathway and the role of nanocarriers: a systematic review. | Kafshdooz L et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| The association between the OPRM1 A118G polymorphism and addiction in a Turkish population. | TΓΌrkan H et al. | β | 2019 | β |
| Drug-Abuse Nanotechnology: Opportunities and Challenges. | Mahmoudi M et al. | β | 2018 | β |
| Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. | Ahmed M et al. | β | 2018 | β |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | β | 2017 | β |
| Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment. | Chatti I et al. | β | 2017 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| A6V polymorphism of the human ΞΌ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. | Knapman A et al. | β | 2015 | β |
| Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human ΞΌ-opioid receptor (OPRM1). | Knapman A et al. | β | 2015 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Case-control association analysis of polymorphisms in the Ξ΄-opioid receptor, OPRD1, with cocaine and opioid addicted populations. | Crist RC et al. | β | 2013 | β |
| Case-control association study of WLS variants in opioid and cocaine addicted populations. | Crist RC et al. | β | 2013 | β |
| Genetic contributions to labor pain and progress. | Landau R | β | 2013 | β |
| Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? | Hall FS et al. | β | 2013 | β |
| Low frequency genetic variants in the ΞΌ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. | Clarke TK et al. | β | 2013 | β |
| Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. | McLemore GL et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs. | Xu Y et al. | β | 2013 | β |
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. | Haerian BS et al. | β | 2013 | β |
| A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. | Crystal HA et al. | β | 2012 | β |
| Association study of the Ξ²-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population. | Ambrose-Lanci LM et al. | β | 2012 | β |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Pharmacogenomic considerations in opioid analgesia. | Vuilleumier PH et al. | β | 2012 | β |
| Pharmacogenomics of opioids and perioperative pain management. | Sadhasivam S et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Genetic variability of pain perception and treatment--clinical pharmacological implications. | LΓΆtsch J | β | 2011 | β |
| Molecular mechanisms of opioid receptor-dependent signaling and behavior. | Al-Hasani R et al. | β | 2011 | β |
| No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. | Nikolov MA et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. | Lloret Linares C et al. | β | 2011 | β |
| Ξ²2-adrenergic receptor genotype and other variables that contribute to labor pain and progress. | Reitman E et al. | β | 2011 | β |
| Association of the functional A118G polymorphism of OPRM1 in diabetic patients with foot ulcer pain. | Cheng KI et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics in obstetric anesthesia. | Landau R et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| Association study of DTNBP1 with schizophrenia in a US sample. | Zuo L et al. | β | 2009 | β |
| Functional characterization of human variants of the mu-opioid receptor gene. | Ravindranathan A et al. | β | 2009 | β |
| Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. | Coller JK et al. | β | 2009 | β |
| Novel linkage disequilibrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population. | Ono T et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. | Pratt WM et al. | β | 2009 | β |
| Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. | Ehlers CL et al. | β | 2008 | β |
| [Genetic polymorphisms and opioid therapies]. | Landau R | β | 2008 | β |
| Pharmacogenetics and obstetric anesthesia. | Landau R | β | 2008 | β |
| Pharmacogenetics of analgesics: toward the individualization of prescription. | Rollason V et al. | β | 2008 | β |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. | Glatt SJ et al. | β | 2007 | β |
| Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. | Bayerer B et al. | β | 2007 | β |
| Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes. | Seno H et al. | β | 2007 | β |
| Pharmacogenetics and obstetric anesthesia. | Landau R | β | 2007 | β |
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. | Kirchheiner J et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| An overview of the genetics of substance use disorders. | Lachman HM | β | 2006 | β |
| Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. | Zhang H et al. | β | 2006 | β |
| Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. | Arias A et al. | β | 2006 | β |
| Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. | Ray R et al. | β | 2006 | β |
| Perspectives on current directions in the neurobiology of addiction disorders relevant to genetic risk factors. | Hurd YL | β | 2006 | β |
| Pharmacogenetics of opioid receptors and addiction. | Mayer P et al. | β | 2006 | β |
| Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. | Oslin DW et al. | β | 2006 | β |
| The mu-opioid receptor gene and smoking initiation and nicotine dependence. | Zhang L et al. | β | 2006 | β |
| The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. | Chong RY et al. | β | 2006 | β |
| Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. | Zhang Y et al. | β | 2005 | β |
| Are mu-opioid receptor polymorphisms important for clinical opioid therapy? | LΓΆtsch J et al. | β | 2005 | β |
| [Are polymorphisms in the mu-opioid receptor important for opioid therapy?]. | LΓΆtsch J et al. | β | 2005 | β |
| Genetic variation in heroin-induced changes in behaviour: effects of B6 strain dose on conditioned reward and locomotor sensitization in 129-B6 hybrid mice. | Szumlinski KK et al. | β | 2005 | β |
| How individual sensitivity to opiates can be predicted by gene analyses. | Ikeda K et al. | β | 2005 | β |
| Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. | Smith RJ et al. | β | 2005 | β |
| Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. | Kreek MJ et al. | β | 2005 | β |
| Pharmacogenetics and nicotine addiction treatment. | MunafΓ² MR et al. | β | 2005 | β |
| Pharmacogenetics: implications for obstetric anesthesia. | Landau R | β | 2005 | β |
| Pharmacotherapy and pharmacogenetics of nicotine dependence. | Berrettini WH et al. | β | 2005 | β |
| Response to Dr. Kopke's comments on haplotypes at the OPRM1 locus. | Luo X et al. | β | 2005 | β |
| The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. | Fillingim RB et al. | β | 2005 | β |
| Treating tobacco dependence: state of the science and new directions. | Lerman C et al. | β | 2005 | β |
| A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. | Ray LA et al. | β | 2004 | β |
| Association of functional opioid receptor genotypes with alcohol dependence in Koreans. | Kim SG et al. | β | 2004 | β |
| Differential expression of mu-opioid receptor gene in CXBK and B6 mice by Sp1. | Lee PW et al. | β | 2004 | β |
| The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. | Lerman C et al. | β | 2004 | β |
| A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. | Oslin DW et al. | β | 2003 | β |